IOM suggests FDA monitor drugs' safety regularly

The Institute of Medicine recommended the FDA oversee drug safety regularly to address additional risks. The FDA indicated reservation about the cost of "life cycle" drug monitoring because this could compromise other regulatory tasks.

View Full Article in:

U.S. needs better way to track drug safety - study - Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN